Cargando…
Oncolytic Rhabdovirus Vaccine Boosts Chimeric Anti-DEC205 Priming for Effective Cancer Immunotherapy
Prime-boost vaccination employing heterologous viral vectors encoding an antigen is an effective strategy to maximize the antigen-specific immune response. Replication-deficient adenovirus serotype 5 (Ad5) is currently being evaluated clinically in North America as a prime in conjunction with oncoly...
Autores principales: | Tzelepis, Fanny, Birdi, Harsimrat Kaur, Jirovec, Anna, Boscardin, Silvia, Tanese de Souza, Christiano, Hooshyar, Mohsen, Chen, Andrew, Sutherland, Keara, Parks, Robin J., Werier, Joel, Diallo, Jean-Simon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658579/ https://www.ncbi.nlm.nih.gov/pubmed/33209979 http://dx.doi.org/10.1016/j.omto.2020.10.007 |
Ejemplares similares
-
The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy
por: Arulanandam, Rozanne, et al.
Publicado: (2020) -
Immunotherapy for sarcomas: new frontiers and unveiled opportunities
por: Birdi, Harsimrat Kaur, et al.
Publicado: (2021) -
CD205 (DEC-205): A recognition receptor for apoptotic and necrotic self
por: Shrimpton, Rachel E., et al.
Publicado: (2009) -
Oncolytic activity of the rhabdovirus VSV‐GP against prostate cancer
por: Urbiola, Carles, et al.
Publicado: (2018) -
The cryo-EM structure of the endocytic receptor DEC-205
por: Gully, Benjamin S., et al.
Publicado: (2020)